Incorporated in 2019, Advit Jewels Ltd is a manufacturer of traditional and contemporary handcrafted fine jewelry.
The company relies on the century-old Rambhajo brand and specialized artisanal craftsmanship in the niche Kundan Polki segment, which is corroborated by high net margins exceeding 20%. However, the lack of scale and the transition from B2B to retail introduces execution risk that could dilute these returns.
Management is pivoting from a capital-light B2B model to a capital-intensive retail and franchise model, including a large 30,000 sq. ft. flagship store. While historical ROCE is high, the negative cash conversion suggests significant capital is being tied up in inventory to support growth.
The transition from a capital-light B2B model to a capital-intensive retail and franchise strategy proved disastrous. The massive 30,000 sq. ft. flagship store and the 30-store expansion plan swallowed the company's cash, as evidenced by the already negative cash conversion cycle. As inventory sat idle—reflected in the declining capacity utilization of 31%—the high historical ROCE collapsed under the weight of heavy working capital requirements. The divergence between revenue growth and plummeting EPS eventually forced a liquidity crunch, proving that the brand could not scale its artisanal niche without destroying its economics.
RichFakir rates Advit Jewels Ltd's business quality as wonderful — 74/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Advit Jewels Ltd is trading about 74% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Advit Jewels Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Advit Jewels Ltd's fair value is about ₹200 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →